Search
Levocabastine
go.drugbank.com/drugs/DB01106ApprovedLevocabastine was discovered at Janssen Pharmaceutica in 1979.
Products: Levocamed 0,5 mg/ml Augentropfensuspension, Levocamed 0,5 mg/ml Nasenspray, SuspensionCholestyramine
go.drugbank.com/drugs/DB01432ApprovedInvestigationalCholestyramine resin is quite hydrophilic, but insoluble in water.
Categories: Compounds used in a research, industrial, or household settingProducts: ANTILIP GRANULADO EN SACHET, COLESTIRAMINA 4 G.FAV-201
go.drugbank.com/drugs/DB06130ExperimentalFAV-201 is a patient-specific immunotherapy for the treatment of T-cell lymphoma.
Heparin
go.drugbank.com/drugs/DB01109ApprovedInvestigationalUnfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. … partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use.
Mixtures: NOSKAR 100 MG/50 IU/10 MG / G, JEL 100 G, NOSKAR 100 MG/50 IU/10 MG / G, JEL 50 GProducts: LIPARIN S SPREY JEL 2400 IU/G KUTANÖZ UYGULAMA İÇİN EMÜLSİYON, 25 G, LIPARIN S SPREY JEL 2400 IU/G KUTANÖZ UYGULAMA İÇİN EMÜLSİYON, 12.5 GAbciximab
go.drugbank.com/drugs/DB00054ApprovedWithdrawnIt also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.
Products: ReoPro 2 mg/ml Injektionslösung oder Infusionslösung, CLOTİNAB 10 MG/5 ML IV ENJEKSİYON İÇİN ÇÖZELTİ İÇEREN FLAKON, 1 ADETCarbidopa
go.drugbank.com/drugs/DB00190ApprovedInvestigationalDue to its activity, carbidopa is always administered concomitantly with [levodopa]. … It potently inhibits aromatic amino acid decarboxylase (DDC) and due to its chemical properties, it does not cross the blood-brain barrier.
Mixtures: LEVO/CA/EN 100/25/200 STD, LEV/CAR/EN AL100/25/200Products: Carbidopa Tablets, 25 mgISB 2001
go.drugbank.com/drugs/DB18570InvestigationalISB 2001 is a T cell-engaging antibody that targets BCMA, CD38, and CD3.
Gadoteridol
go.drugbank.com/drugs/DB00597ApprovedInvestigational[A263076] Initially approved by the FDA in 1992, gadoteridol received additional approval in 2020 for use in pediatric patients less than 2 years old.[L49876] … [A263076,A263081,L49871] It was 1 of the 3 macrocyclic gadolinium-based contrast agents (GBCAs) that was mandated by the EMA to replace linear gadolinium-based contrast agents due to concerns about retained
Synonyms: GD-HP-DO 3ACategories: Compounds used in a research, industrial, or household settingPovidone-iodine
go.drugbank.com/drugs/DB06812ApprovedInvestigationalShelanski and M. V. Shelanski. During in vitro testing to demonstrate anti-bacterial activity it was found that the complex was less toxic in mice than tincture of iodine. … It contains from 9.0% to 12.0% available iodine, calculated on a dry basis. This unique complex was discovered in 1955 at the Industrial Toxicology Laboratories in Philadelphia by H. A.
Mixtures: P-Care MG, Physicians EZ Use M-predCategories: Compounds used in a research, industrial, or household settingRamucirumab
go.drugbank.com/drugs/DB05578ApprovedInvestigationalBy binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, … In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it.
Products: CYRAMZA 500 MG/50 ML İNFÜZYONLUK ÇÖZELTİ KONSANTRESİ İÇEREN FLAKON, 1 ADET, CYRAMZA 100MG/10 ML INFÜZYONLUK ÇÖZELTI KONSANTRESI IÇEREN FLAKON, 1 ADET